Loading
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Previous close
$2.03
−$0.01 · -0.49%
After-hours
$2.00
−$0.03 · -1.48%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Day range
Current $2.03
52-week range
Current $2.03
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
41
Fair Value
Sentiment
49
Mixed
Risk
73
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Day range
Current $2.03
52-week range
Current $2.03
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
